Steve Soper,
Foundation Distinguished Professor, Director, Center of BioModular Multi-Scale System for Precision Medicine,
The University of Kansas
Prof. Soper is currently a Foundation Distinguished Professor in Chemistry and Mechanical Engineering at the University of Kansas, Lawrence. Prof. Soper also holds an appointment at Ulsan National Institute of Science and Technology in Ulsan, South Korea, where he is a World Class University Professor. He is also serving as a Science Advisor for a number of major worldwide companies. Prof. Soper is currently on the Editorial Board for Scientific Reports and Journal of Micro- and Nanosystems.
As a result of his efforts, Prof. Soper has secured extramural funding totaling >$103M and has published over 265 peer-reviewed manuscripts (h index = 71) and is the author of 20 patents. He is also the founder of a startup company, BioFluidica, which is marketing devices for the isolation and enumeration of circulating tumor cells. His list of awards includes Chemical Instrumentation by the American Chemical Society, the Benedetti-Pichler Award for Microchemistry, Fellow of the AAAS, Fellow of Applied Spectroscopy, Fellow of the Royal Society of Chemistry, R&D 100 Award, Distinguished Masters Award at LSU and Outstanding Scientist/Engineer in the state of Louisiana in 2001. Finally, Prof. Soper has granted 60 PhDs and 6 MS degrees to students under his mentorship. He currently heads a group of 20 researchers.
Screening Tests Using Micro- and Nanofluidics for Early Disease Detection at the Point-of-Care
Monday, 19 June 2023 at 17:30
Add to Calendar ▼2023-06-19 17:30:002023-06-19 18:30:00Europe/LondonScreening Tests Using Micro- and Nanofluidics for Early Disease Detection at the Point-of-CareCirculating Biomarkers and Extracellular Vesicles Europe 2023 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com
We are developing screening tests consisting of novel hardware, biomarkers, and assays to service a number of diseases, including the early detection of cancer and viral infections. The commonality in these tests is that they consist of microfluidic devices made from plastics via injection molding. Thus, our tests can be mass produced at low-cost that facilitates bench-to-bedside transition and point-of-care testing (PoCT) for large scale screening. The assays are based on the use of liquid biopsy markers as the input, which can be secured in a non- to minimally-invasive manner appropriate for screening. Recently we have focused on developing plastic nanofluidic devices, which provides unique opportunities for single-entity analyses. In this presentation, we will talk about the evolution of our fabrication efforts of plastic-based microfluidic and nanofluidic devices as well as their surface modification to make devices biocompatible. Then, we will discuss two applications of these devices and the assays for selection of rare liquid biopsy targets from clinical samples to serve as screening tests: (1) Analysis of extracellular vesicles (EVs) for the early detection of ovarian cancer; and (2) detection of viral particles from saliva samples, in particular SARS-CoV-2. Ovarian cancer is the 5th most deadly cancer for women in the US and has a 46.2% 5-y survival rate. Unfortunately, ~85% of cases are diagnosed at a late stage of disease, which demands new strategies for early detection. The screening test we are developing consists of a microfluidic chip for EV selection, which consists of a high density array of pillars surface-decorated with antibodies to efficiently select EVs followed by the label-free enumeration to determine elevated levels of EVs in the plasma of patients suspected of having ovarian cancer. Unique surface proteins were discovered for selection of ovarian cancer EV selection specifically for the early detection of disease. The infectious disease diagnostic accepts saliva samples and searches for viral particles using aptamers and counts the number of viral particles. For both disease examples, the selected particles were counted using a label-free approach; nano-Coulter Counter chip (nCC) consisting of in-plane nanopores. Both steps of the screening test described here were carried out using a microfluidic and nanofluidic chip. The chips were integrated to a control board for automating sample processing with results in <20 min.
Add to Calendar ▼2023-06-19 00:00:002023-06-20 00:00:00Europe/LondonCirculating Biomarkers and Extracellular Vesicles Europe 2023Circulating Biomarkers and Extracellular Vesicles Europe 2023 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼2023-06-19 17:30:002023-06-19 18:30:00Europe/LondonScreening Tests Using Micro- and Nanofluidics for Early Disease Detection at the Point-of-CareCirculating Biomarkers and Extracellular Vesicles Europe 2023 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com
